Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.

Request To Download Free Sample of This Strategic Report @ Highlighted with 39 tables and 46 figures, this 120-page report Asia Pacific Transcriptomics Market 2021-2031 by Component (Instruments, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 42 tables and 37 figures, this 121-page report Europe Transcriptomics Market 2021-2031 by Component (Instruments, ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

Sensitive instruments, such as flow cytometry and microarrays, are essential tools. Janssen, Life Sciences Vision, Front Line Genomics, and Trivitron Healthcare are also significant players. Raw ...